



Addressing the Public Health Effects of Opioid Medications

September 9, 2026 | 12:30 – 4:30pm ET

IN PERSON

FDA White Oak Campus, Building 31 Great Room
10903 New Hampshire Avenue, Silver Spring, MD 20993

VIRTUAL

Webinar link provided upon registration

Agenda

12:30pm	Welcome Susan C. Winckler, RPh, Esq, CEO, Reagan-Udall Foundation for the FDA
12:35pm	Opening Remarks Michael Davis, MD, PhD, Director, Center for Drug Evaluation and Research (CDER), FDA
12:40pm	Federal Partner Panel • Timothy J. Atkinson, PharmD, Acting Director, Opioid Safety, Specialty Care Program Office, U.S. Department of Veterans Affairs • Robert Baillieu, MD, MPH, Physician & Senior Advisor, Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, • Wilson M. Compton, MD, MPE, Deputy Director, National Institute on Drug Abuse • Kristine Schmit, MD, MPH, Medical Officer, Health Systems and Research Branch, Division of Overdose Prevention, U.S. Centers for Disease Control and Prevention • Marta Sokolowska, PhD, Deputy Center Director for Substance Use and Behavioral Health, CDER, FDA
1:30pm	Public Comment TOPICS 1. Scientific evidence regarding conditions of use, safety concerns, or benefit-risk assessment (including consideration of the public health effects) of opioid medications 2. Input on FDA's regulation of opioid medications 3. Additional actions that could be considered to address the public health effects of opioid medications
2:30pm	BREAK
2:45pm	Public Comment <i>continued</i>
4:30pm	Adjourn

This project is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of an award of \$117,983 in federal funds (100% of the project). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by FDA, HHS, or the U.S. Government. For more information, please visit [FDA.gov](https://www.fda.gov)